We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Medical Marijuana Use in HIV+ Patients: Probability Survey (MMS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01536912
First Posted: February 22, 2012
Last Update Posted: July 30, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Mark Greenwald, PhD, Wayne State University
  Purpose

More scientific information is needed about medical marijuana use among HIV positive patients. There is conflicting information about the use of marijuana, use of medical marijuana, and the associations between them and health status/health risk behaviors/health care utilization. In addition, it is not clear whether patients who participate in prospective clinical studies differ from participants who do not participate; if there are differences between those two groups, then this would limit generalizability of knowledge about these issues.

The goal of this project is to describe the use of marijuana among HIV positive patients and its association with health status/health risk behaviors/health care utilization.


Condition
HIV Positive

Study Type: Observational
Study Design: Observational Model: Case-Only
Official Title: Behavioral Economic Analysis of Medical Marijuana Use in HIV+ Patients: Probability Survey

Resource links provided by NLM:


Further study details as provided by Mark Greenwald, PhD, Wayne State University:

Enrollment: 218
Study Start Date: February 2012
Study Completion Date: December 2014
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Detailed Description:

Participants will answer questions about marijuana, medical marijuana, and other drug use. We will also ask about health and steps participants take to keep healthy. The study will take up to one hour to complete.

Participants will also be asked to sign a release of information form. This form would allow us to look at medical records at the HIV clinic.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
HIV positive
Criteria

Inclusion Criteria:

  • Patients in the HIV clinic
  • HIV positive

Exclusion Criteria:

  • Lack of english
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01536912


Locations
United States, Michigan
Wayne State University (HIV clinic, Tolan Park Medical Building)
Detroit, Michigan, United States, 48201
Sponsors and Collaborators
Wayne State University
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Mark Greenwald, PhD Wayne State University
  More Information

Responsible Party: Mark Greenwald, PhD, Professor, Wayne State University
ClinicalTrials.gov Identifier: NCT01536912     History of Changes
Other Study ID Numbers: MMS-1
R01DA032678 ( U.S. NIH Grant/Contract )
First Submitted: February 16, 2012
First Posted: February 22, 2012
Last Update Posted: July 30, 2015
Last Verified: July 2015

Keywords provided by Mark Greenwald, PhD, Wayne State University:
HIV positive

Additional relevant MeSH terms:
HIV Seropositivity
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases